All In Biotech

Drug Trial Radar · NCT07288359

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

An Open-label, Multi-center, Phase I/II Study of GVV858 as a Single Agent and in Combination With Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2- Negative Breast Cancer and Other Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 205 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

205

Planned (sponsor's estimate)

Start

Dec 29, 2025

Primary completion

May 9, 2031

Study completion May 9, 2031

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Dec 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase I: Characterize safety and tolerability of GVV858 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimization/recommended dose for further clinical evaluation. Phase II: Further characterize the safety and tolerability of GVV858 in combination with fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.

Conditions

  • Advanced HR+/HER2- Breast Cancer
  • Advanced CCNE1-amplified Solid Tumors
  • Metastatic Castration-resistant Prostate Cancer

Interventions

  • GVV858Drug

    Experimental

  • FulvestrantDrug

    Approved medication

  • LetrozoleDrug

    Approved medication

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I: Incidence and severity of dose-limiting toxicities (DLTs)Time frame: 28 days
  2. Phase I and phase II: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)Time frame: Up to approximately 2 years
  3. Phase I and phase II: Frequency of dose interruptions, reductions and discontinuationsTime frame: Up to approximately 2 years
  4. Phase I and phase II: Dose intensityTime frame: Up to approximately 2 years

Locations

16 sites in 11 countries. Site status is shown where the registry gives one.

  • Emory University

    Atlanta, Georgia · Recruiting

  • Tennessee Oncology PLLC

    Nashville, Tennessee · Recruiting

  • START

    San Antonio, Texas · Recruiting

  • Novartis Investigative Site

    Toronto, Ontario, Canada · Recruiting

  • Novartis Investigative Site

    Olomouc, Czechia · Recruiting

  • Novartis Investigative Site

    Odense C, Denmark · Recruiting

  • Novartis Investigative Site

    Pierre-Bénite, France · Recruiting

  • Novartis Investigative Site

    Essen, Germany · Recruiting

  • Novartis Investigative Site

    Jena, Thuringia, Germany · Recruiting

  • Novartis Investigative Site

    Milan, MI, Italy · Recruiting

  • Novartis Investigative Site

    Milan, MI, Italy · Recruiting

  • Novartis Investigative Site

    Kyoto, Japan · Recruiting

  • Novartis Investigative Site

    Singapore, Singapore · Recruiting

  • Novartis Investigative Site

    Barcelona, Spain · Recruiting

  • Novartis Investigative Site

    Madrid, Spain · Recruiting

  • Novartis Investigative Site

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.